SJF620

Target: SJF620 selectively targets Bruton’s tyrosine kinase for cereblon-mediated degradation.

Binding site: Its BTK ligand binds the ATP-binding catalytic pocket of BTK.

Mechanism of action: SJF620 is a potent CRBN-recruiting BTK PROTAC that links a BTK-binding ligand to a lenalidomide-derived cereblon recruiter. By simultaneously engaging BTK and CRL4CRBN, SJF620 drives ternary-complex formation, BTK ubiquitination, and proteasome-dependent degradation. This event-driven mechanism enables depletion of BTK protein rather than transient inhibition of its catalytic activity. In research studies, SJF620 supports analysis of B-cell receptor signaling, BTK protein dependency, degradation kinetics, downstream pathway suppression, and comparison of degradation-based BTK modulation with conventional covalent or reversible kinase inhibition.

• PROTAC-Mediated Kinase Degradation: SJF620 serves as a powerful tool for the targeted degradation of kinases, offering researchers a novel approach to dissect kinase signaling pathways. By leveraging the PROTAC mechanism, SJF620 facilitates the precise removal of specific kinases, enhancing the study of their biological roles and potential as therapeutic targets.

• Targeted Protein Degradation in Cancer Research: SJF620 is utilized in cancer research to selectively degrade oncogenic proteins. This approach allows scientists to investigate the effects of protein depletion on cancer cell viability and proliferation, providing insights into potential vulnerabilities that can be exploited for therapeutic intervention.

• Elucidation of Protein Function via PROTACs: Researchers employ SJF620 to study protein function by inducing targeted protein degradation. This method enables the exploration of protein roles in various cellular processes, facilitating the identification of critical proteins involved in disease mechanisms and offering a pathway to novel drug discovery.

• PROTAC-Based Drug Discovery: SJF620 is instrumental in drug discovery efforts focused on targeted protein degradation. By enabling the selective elimination of disease-associated proteins, it aids in the identification and validation of new drug targets, accelerating the development of innovative therapeutic strategies.